Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IDYA
SellSinkerIDEAYA Biosciences, Inc. · Healthcare · United States · $3.9B · Avg Vol: $27M/d
COMPANY DESCRIPTION
IDEAYA Biosciences, Inc. is a clinical-stage oncology-focused biotechnology company pioneering the field of synthetic lethality to develop targeted therapeutics. The company's competitive moat is established by its industry-leading pipeline of precision medicine candidates and its proprietary biomarker discovery platform. It operates as a premier biotechnology innovator with strategic development partnerships alongside global pharmaceutical giants.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.9M | 23.4M | 7.0M | 218.7M | 62.5% | 234.1M | 39.4M | 115.5M | -27.3% |
| EPS | -1.42 | -1.96 | -3.36 | -1.28 | — | -1.92 | — | — | — |
| Shares | 48.2M | 65.0M | 86.5M | 87.8M | +82.2% | 96.5M | — | — | — |
| Debt | 3.5M | 2.9M | 19.2M | 27.9M | 100.1% | 29.3M | — | — | — |
| Equity | 349.5M | 621.1M | 1.1B | 1.0B | 43.0% | — | — | — | — |
| Op CF | -87.2M | -115.2M | -247.6M | -71.1M | — | -111.7M | — | — | — |
| Inv CF | -33.4M | -158.5M | -502.6M | 70.0M | — | — | — | — | — |
| Fin CF | 97.2M | 362.7M | 677.6M | 29.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IDYA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IDYA | IDEAYA Biosciences, Inc.(you) | $3.9B | 21 | Sell |
| DNLI | Denali Therapeutics Inc. | $3.8B | 21 | Sell |
| MANE | Veradermics, Incorporated | $4.1B | 22 | Sell |
| VKTX | Viking Therapeutics, Inc. | $3.8B | 18 | Strong Sell |
| TNGX | Tango Therapeutics, Inc. | $3.9B | 17 | Strong Sell |
| IMNM | Immunome, Inc. | $3.1B | 20 | Strong Sell |
| IRON | Disc Medicine, Inc. | $3.1B | 22 | Sell |
| RCUS | Arcus Biosciences, Inc. | $3.7B | 14 | Strong Sell |
| DFTX | Definium Therapeutics, Inc. | $5.5B | 22 | Sell |
| RLAY | Relay Therapeutics, Inc. | $4.1B | 28 | Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.3%